For the latest ecancer COVID-19 resources, click on this link

ASH 2020: Targeted therapies in r/r multiple myeloma

Bookmark and Share

ASH 2020

3 - 8 Dec 2020

Please rate this video

The information in this video was of interest to me

The information in this video is likely to improve my clinical practice or research

I would recommend this video to my colleagues
Published: 8 Dec 2020
Views: 2678
Rating:
Save
Prof Marivi Mateos, Prof Meletios Dimopoulos, Prof Meral Beksaç, Dr Shaji Kumar

Prof Marivi Mateos (University of Salamanca, Spain) chairs an expert discussion with Prof Meletios Dimopoulos (University of Athens, Greec), Dr Shaji Kumar (Mayo Clinic, Rochester, USA) and Prof Meral Beksaç (Ankara University, Turkey) on the latest in targeted therapy for multiple myeloma from ASH 2020.

They discuss all the updates from this year’s ASH conference regarding targeted therapies for R/R multiple myeloma including the FORTE, APOLLO, IKEMA, ICARIA-MM and MAIA studies.

They also touch on the latest in newly diagnosed multiple myeloma and discuss the use of immunotherapy and CAR-T cells.

ecancer's filming has been kindly supported by Sanofi through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

 

Related Videos

Long-term follow-up of low-intensity chemotherapy with combination therapy for r...
Prof Hagop Kantarjian - MD Anderson Cancer Center, Houston, USA
Long-term follow-up of low-intensity chemotherapy with combination therapy for r/r Ph- acute lymphoblastic leukaemia patients ( Prof Hagop Kantarjian - MD Anderson Cancer Center, Houston, USA )
22 Dec 2020
Real-world evidence of the use of carfilzomib among multiple myeloma patients ac...
Prof Evangelos Terpos - University of Athens, Athens, Greece
Real-world evidence of the use of carfilzomib among multiple myeloma patients across 10 European countries and Israel ( Prof Evangelos Terpos - University of Athens, Athens, Greece )
22 Dec 2020
Real-world evidence of the use of carfilzomib to refractory to lenalidomide pati...
Prof Evangelos Terpos - University of Athens, Athens, Greece
Real-world evidence of the use of carfilzomib to refractory to lenalidomide patients ( Prof Evangelos Terpos - University of Athens, Athens, Greece )
22 Dec 2020
A treatment comparison of carfilzomib, dexamethasone and daratumumab to daratumu...
Prof Evangelos Terpos - University of Athens, Athens, Greece
A treatment comparison of carfilzomib, dexamethasone and daratumumab to daratumumab and bortezomib ( Prof Evangelos Terpos - University of Athens, Athens, Greece )
22 Dec 2020
ASH 2020: Immunotherapy in relapsed/refractory multiple myeloma
Dr Robert Rifkin, Prof Sagar Lonial, Prof Evangelos Terpos, Dr Nina Shah, Dr Eri...
ASH 2020: Immunotherapy in relapsed/refractory multiple myeloma ( Dr Robert Rifkin, Prof Sagar Lonial, Prof Evangelos Terpos, Dr Nina Shah, Dr Eric Smith )
15 Dec 2020
MURANO: Sustained disease survival in CLL following venetoclax plus rituximab
Dr Arnon Kater - Cancer Center Amsterdam, Amsterdam, Netherlands
MURANO: Sustained disease survival in CLL following venetoclax plus rituximab ( Dr Arnon Kater - Cancer Center Amsterdam, Amsterdam, Netherlands )
9 Dec 2020
Comparing outcomes of first-line ibrutinib vs chemoimmunotherapy in high-risk CL...
Dr Lori Leslie - John Theurer Cancer Center, Hackensack, USA
Comparing outcomes of first-line ibrutinib vs chemoimmunotherapy in high-risk CLL ( Dr Lori Leslie - John Theurer Cancer Center, Hackensack, USA )
9 Dec 2020
Five year update of ECHELON-1 for classical Hodgkin lymphoma
Dr Otavio Baiocchi - Centro Especializado em Oncologia, São Paulo, Brazil
Five year update of ECHELON-1 for classical Hodgkin lymphoma ( Dr Otavio Baiocchi - Centro Especializado em Oncologia, São Paulo, Brazil )
8 Dec 2020
Blinatumomab and oral TKIs for the treatment of Ph ALL
Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA
Blinatumomab and oral TKIs for the treatment of Ph ALL ( Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA )
8 Dec 2020

More from ecancer

Stay up to date with our ecancer newsletter

Learn more

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

Learn more

Support ecancer's work by making a donation